Premium
Unrelated donor bone marrow transplantation in children and young adults with acute myeloid leukaemia in remission
Author(s) -
Chown Sally R.,
Marks David I.,
Cornish Jacqueline M.,
Pamphilon Derwood H.,
Potter Michael N.,
Steward Colin G.,
Oakhill Anthony
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.3593173.x
Subject(s) - medicine , bone marrow , transplantation , complete remission , myeloid , surgery , chemotherapy
The role of unrelated donor bone marrow transplantation (UD‐BMT) in the management of patients with acute myeloid leukaemia (AML) is uncertain. We describe 18 patients with a median age of 13 years (range 4–31) who received an ex vivo T‐cell‐depleted UD‐BMT for AML (13 in second complete remission (CR2) and five in first complete remission (CR1) with high‐risk features). Nine donor recipient pairs were fully matched; eight of these donor–recipient pairs had a single class I HLA mismatch; one patient had both single class I and class II HLA mismatches. Grade II GVHD of the skin occurred in four patients (22%) and limited chronic GVHD in two patients (11%). There have been four deaths: one from relapse and three from infection. With a median follow‐up of 27 months, 14 patients survive and the actuarial event‐free survival at 2 years is 70 ± 20% (95% confidence interval). We conclude that unrelated donor BMT can result in prolonged disease‐free survival in children and young adults with AML.